Single-cell Omics Market Share

North American Market Forecast

The North America single-cell omics market held over 46% of the revenue share in 2022 and is projected to be the largest with a share of about nearly 40% by the end of 2035. The growth of the market is credited to rising investment in advanced healthcare technologies. Approximately USD 31 billion was invested in healthcare technology enterprises in the United States in the first quarter of 2022, which represents 28% of total investments. Investments in healthcare technologies, such as genomics, molecular diagnostics, and bioinformatics, support the development of precision medicine approaches. The integration of single-cell omics with healthcare technologies enables more accurate disease characterization, and patient stratification, driving the demand for single-cell omics technologies in the region.

APAC Market Statistics

The Asia Pacific single-cell omics market is expected to be the second largest, with a share of over 27% by the end of 2035, rising at a CAGR of almost 18% over the anticipated period. The rise in the collaboration of companies will bring new opportunities for market growth. For instance, Mission Bio, an innovator in high-throughput single-cell DNA and multi-omics analysis, recently signed a collaboration contract with SequMed, a Chinese pioneer in single-cell omics technology invention and applications. The partnership will allow Mission Bio's technological platform to be combined the clinical assay development and data analysis capabilities of SequMed in order to jointly create advanced single-cell assays for cancer detection, medication counseling, and prognostic tracking in China.

Frequently Asked Questions (FAQ)

Increasing incidences of cancer, rising investment in cell therapy, and technological advancement of single-cell techniques are the major factors driving the market growth.

The market size of single-cell omics is anticipated to attain a CAGR of around 22% over the forecast period, i.e., 2023 â€“ 2035.

The major players in the market are 10x Genomics, Inc., Becton, Dickinson and Company (BD), CELLENION, PerkinElmer Inc., ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc., Mission Bio Inc., Standard BioTools Inc. and Ultima Genomics, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, product, end user, and by region.

The oncology segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

There is no standardization and the higher cost of single-cell omics is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Single-cell Omics Market Share